Adeyemi, Olanrewaju Sanjo1,2, *, Kehinde, Ibrahim Oluwatobi 3, Abiola, Julianah Ore 1,2, Omotuyi, Idowu Olaposi 2,3
and Oyinloye, Babatunji Emmanuel 1,2
1Biochemistry Programme, Department of Chemical Sciences, College of Sciences, Afe Babalola University, Ado-Ekiti, Nigeria;
2Institute of Drug Research and Development, SE Bogoro Center, Afe Babalola University, Ado-Ekiti, Nigeria;
3Department of Pharmaceutical Science, Faculty of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria
Abstract: Ageing is the accelerated loss of forms and functions of cellular
components. Pathological ageing affects every human. AMP-activated protein
kinase (AMPK) and Mammalian target of rapamycin (mTOR) mTOR proteins play
major roles in maintaining cellular energy homeostasis by noticing and responding
to AMP/ATP level and nutrients for protein synthesis. AMPK and mTOR have been
implicated in various spectrum of aging-associated diseases like cancer, diabetes
and cardiovascular diseases. Inhibition of mToR protein has been engaged in the
treatment of diseases by targeting the P13k/AKT pathway while the activation of
AMPK is believed to extend lives. This computational approach compares
phytochemicals from T. foenum in activation of AMPK to a standard drug
(segluromet) in clinical trial and the inhibitory capacity of T. foenum on MToRC1
complex through the FK506 Binding Protein binary complex which interact with
the mToR protein, also compared with SAFIT2 and rapamycin which inhibit mTOR
to bring about autophapy or inhibition of protein synthesis and fat accumulation in
the body. Our result shows that T foenum phytochemicals could be considered as
potential AMPK activators and Inhibitors of mTOR pathway. Hence, we can
recommend it for in vivo study.
Keywords: Ageing, AMPK, mTOR Protein, T. foenum, Seglurome.
